Medical Pharmacology Chapter 25: Pulmonary Pharmacology Practice Questions

Higher endothelin levels are associated with which one(s) of the following
1. Increased mean pulmonary arterial pressure (mPAP)
2. Increased pulmonary vascular resistance (PVR)
3. Both
4. Neither
Elevated endothelin levels are associated with which one(s) of the following?
1. Reduced cardiac output
2. Reduced 6 minute walk distance (6MWD)
3. Both
4. Neither
Endothelin receptor antagonist inhibit endothelin-1 (ET-1) binding to endothelin receptor ET-A) and/or endothelin receptor B (ET-B).
1. True
2. False
Endothelin receptor A (ET-A) is mainly found on pulmonary artery smooth muscle cells. Activation of these receptors induced vasoconstriction.
1. True
2. False
Normally, endothelin receptor B (ET-B) are localized on endothelial cells.
1. True
2. False
Factor/factors associated with endothelin receptor B mediated vasodilation:
1. Increased endothelin-1 clearance
2. Increased prostacyclin synthesis
3. Increased nitric oxide levels
4. A & B
5. B & C
6. A & C
7. A, B & C
Choose (the) endothelin receptor antagonist(s) from the following:
1. Macitentan (Opsumit)
2. Bosentan (Tracleer)
3. Ambrisentan (Letairis)
4. A & B
5. B& C
6. A & C
7. A, B & C
This agent is a selective endothelin receptor A (ET-A) antagonist.
1. Bosentan
2. Ambrisentan
3. Macitentan
Bosentan and macitentan represent nonselective endothelin receptor blockers.
1. True
2. False
Choose (the) correct statement(s) from the following:
1. Sildenafil is an example of a phosphodiesterase type-5 inhibitor used in treating pulmonary hypertension.
2. Tadalafil is a phosphodiesterase type-5 inhibitor used in treating pulmonary hypertension.
3. Ricociguat Is an oral soluble guanylyl cyclase stimulator that may be used for treating pulmonary hypertension and chronic thromboembolic pulmonary hypertension CTEPH)
4. A & B
5. B & C
6. A & C
7. A, B & C